alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 10.1


Fintel (USA) Limited


602 Nan Fung Tower, 88 Connaught Road Central,
Hong Kong


 


 





	Gold Billion Group Holdings Limited	1 March, 2016






Room 1202A, Empire Center


68 Mody Road, TsimShaTsui


Kowloon


 


Dear Sir,


 


We are pleased to outline the service we are prepared to provide
to your company and the related fee below:


 


Service to be provided:


 


		1.	Preparation of the required quarterly and annual filings;



		2.	Coordination with the auditor on audit and review of financial statements and filings;



		3.	Coordination with filing agent on matters relating to filing of required reports and forms;



		4.	Coordination with stock transfer agent on issuance and transfer of share certificates;



		5.	Communication with legal advisors on the normal operation of company;



		6.	Communication with the company’s registration agent.



 


Note: Gold Billion Group Holdings Limited will prepare its financial
statements in accordance to the relevant account guidelines to meet reporting requirement.


 


Fee:


 


Our fee for the above service shall be US$1,700 per month payable
quarterly in advance. Please note that this fee assumes that your business operation remains at the present state. All out-of-pocket
expenses shall be for the account of the company. If Gold Billion Group Holdings Limited acquires other business and assets or
enters into new business development, the fee will be revised to reflect the additional work load, if any.


 


Commencement:


 


The commencement date of the service shall be 1 May, 2016.


 


If you find the above correctly outlines our understanding,
please confirm by signing at the space provided below and return to us a copy of this letter. We thank you for giving us the opportunity
to be of service.


 





	For and on behalf of	Agreed and confirmed by
	Fintel (USA) Limited	Gold Billion Group Holdings Limited
	 	 
	/s/ Stephen Tang                           	/s/ KOK Seng Yeap                       
	Authorized Signature	Authorized Signature
EXHIBIT 32.1




CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18
U.S.C. SECTION 1350




Pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, I, Gordon Ellis, President and Chief Executive Officer, certify
that:




1. To my knowledge, this report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and




2. To my knowledge, the information in this report fairly
presents, in all material respects, the financial condition and results of operations of International Absorbents Inc. as of October 31,
2007.







|Date: December
13, 2007 |  |  |  | /s/
GORDON ELLIS                                 
|----------------------- |  |  |  | -------------------------------------------------
|                       
|                        |  |  |  | Gordon
EllisPresident and Chief Executive Officer

---
#### Joyce et al. v. Dulaney

*Harold V. Fergus*and *Thomas H. Cauley,*for plaintiffs.

*Louis R. Oppenheim,*for defendant.

*382June 25, 1951.

Per Curiam,

— The two plaintiffs brought an action of trespass against defendant. The complaint filed appears to be the complaint of one of the plaintiffs, without indicating which one, and in some parts seems to claim damages on behalf of each, and finally claims damages in a lump sum for both.

Under Pa. R. C. P. 2229 it is permissible for plaintiffs to join to secure relief jointly, severally, or separately, or in the alternative with respect to the one accident averred. If they do so, then they must comply with Pa. R. C. P. 1020(6), which requires any special damages and the demand for relief of each plaintiff to be set forth in a separate count preceded by the appropriate heading.

From an examination of the complaint filed in this case, it is clear that the procedural rules have not been complied with.

And now, June 25, 1951, the preliminary objections filed by defendant are sustained, and it is ordered that the complaint in trespass heretofore filed in this action be stricken from the record, with leave to plaintiffs to filed a proper complaint on or before the fourth Monday of August next.
J~~~EO srqT~

s 

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

Q WASHINGTON, D.C. 20460 

z ~l~(/► ~ 0 

PROS ~G~` 

OFFICE OF 

AIR AND RADIATION 

OCT ® 2 2014 

Ann Lee-Jeffs 

Leader, Product Stewardship 

Honeywell International Inc. 

101 Columbia Road 

Morristown, NJ 07962-1039 

Re: Completeness Determination for SNAP Submission for Solstice ® N-13 in Refrigeration 

and Air Conditioning. 

Dear Ms. Lee-Jeffs: 

Thank you for Honeywell's submission to the Environmental Protection Agency (EPA) for 

Solstice ® N-13 in refrigeration and air conditioning. EPA established the Significant New 

Alternatives Policy (SNAP) program to implement section 612 of the Clean Air Act. Your 

submission received on May 29, 2014 has been reviewed for completeness. We have found the 

information to be complete. 

Here is a summary of information concerning your submission: 

Substitute name: Solstice ® N-13 

Sector: Refrigeration and Air Conditioning 

End uses: Retail food, refrigerated transport, vending, water coolers, cold water storage 

warehouses, industrial process refrigeration, chillers, domestic refrigerators, cascade 

refrigeration systems, industrial process air-conditioning. 

New or retrofit usage: Retrofits and New Equipment 

Date received: May 29, 2014 

Date of most recent information received: September 16, 2014 

Status of submission: Complete 

Your submission was complete as of September 16, 2014. EPA has 90 days from this date to 

render a decision about the acceptability of Solstice ® N-13 in the specified end-uses. You may , 

Internet Address (URL) • http //www.epa.gov 

RecycledlRecyclabte • Printed with Vegetable Oil Based Inks on 100% Postconsumer. Process Chlorine Free Recycled Paper 
sell or import Solstice ® N-13 for use in the refrigeration and air conditioning end-uses described 

above as of December 15, 2014. If you have questions about your submission, please me at (202) 

343-9624 orWozniak.eg rald~epa.go_v. 

Sincerely, 

X4, Z.." 

Gerald Wozniak 

Alternatives and Emissions Reduction Branch 

Stratospheric Protection Division
### Ground-water resources of Hamilton County, Nebraska, with a section on the chemical quality of the water

By: Charles Franklin KeechP. G. Rosene

                            https://doi.org/10.3133/wsp1539N

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf) 
- NGMDB Index Page:  **National Geologic Map Database Index Page**                            (html)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
<PAGE>   1
                                                                     Exhibit 4.3



                        SEE RESTRICTIONS ON REVERSE SIDE


            NUMBER                   [LOGO]                   SHARES


                           A-FEM MEDICAL CORPORATION


                            ORGANIZED UNDER THE LAWS
                             OF THE STATE OF NEVADA

THIS CERTIFIES THAT                            is the registered holder 
of                           Shares                   of the Series A 
Convertible Preferred Stock, $.01 par value per share, transferable only on the 
books of the Corporation by the holder hereof in person or by Attorney upon 
surrender of this Certificate properly endorsed.

IN WITNESS WHEREOF, the said Corporation has caused this Certificate to be 
signed by its duly authorized officers and its Corporate Seal to be hereunto 
official      this     day               of                      A.D.19


   ----------------------             [LOGO]          -----------------------
        President                                                Secretary
<PAGE>   2
The securities evidenced by this Certificate have not been registered under the
Securities Act of 1933, as amended (the "Act"), or any applicable state law, and
no interest therein may be sold, distributed, assigned, offered, pledged or
otherwise transferred unless (a) there is an effective registration statement
under such Act and applicable state securities laws covering any such
transaction involving said securities or (b) this corporation receives an
opinion of legal counsel for the holder of these securities (concurred in by
legal counsel for this corporation) stating that such transaction is exempt from
registration or this corporation otherwise satisfies itself that such
transaction is exempt from registration. Neither the offering of the securities
nor any offering materials have been reviewed by an administrator under the Act
or any applicable state law.

Upon written request, the Corporation will furnish to any shareholder, without 
charge, a full statement of the designation, preference, limitations, and 
relative rights applicable to the shares of each class of stock authorized to 
be issued and, with respect to any preferred or special class which the 
Corporation is authorized to issue in series, the variations in rights, 
preferences and limitations for shares of each such series, so far as the same 
have been fixed and determined, and the authority of the Board of Directors to 
fix and determine the relative rights and preferences of subsequent series.


                     [back of preferred stock certificate]
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1206 Calcium iodate. ( a ) Calcium iodate [Ca(IO3)2·H2O, CAS Reg. No. 7789-80-2], also referred to as lautarite, does not occur naturally but can be prepared by passing chlorine into a hot solution of lime (CaCO3) in which iodine has been dissolved.
( b ) The ingredient meets the specifications of the “Food Chemicals Codex,” 3d Ed. (1981), p. 53, which is incorporated by reference. Copies may be obtained from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) The ingredient is used as a dough strengthener as defined in § 170.3(o)(6) of this chapter.
( d ) The ingredient is used in the manufacture of bread in accordance with § 184.1(b)(2) of this chapter in an amount not to exceed 0.0075 percent based on the weight of the flour.
( e ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[43 FR 11699, Mar. 21, 1978, as amended at 49 FR 5611, Feb. 14, 1984]
<PAGE>   1
                                                                    EXHIBIT 23.3


                        CONSENT OF INDEPENDENT AUDITORS

The Board of Directors
Logical Software Solutions Corporation:

We consent to the incorporation by reference herein of our report dated June 
30, 1998, with respect to the balance sheet of Logical Software Solutions 
Corporation as of December 31, 1997, and the related statements of operations,
stockholders' equity, and cash flows for the year then ended, which report 
appears in the June 30, 1998, current report on Form 8-K/A of INTERLINQ Software
Corporation and to the reference to our firm under the heading "Experts" in the 
Proxy Statement/Prospectus.


KPMG LLP

Seattle, Washington
January 22, 1999
§ 556.115 Cephapirin. ( a ) [Reserved]
( b ) *Tolerances.* The tolerances for cephapirin are: ( 1 ) *Cattle.* ( i ) Edible tissues (excluding milk): 0.1 ppm.
( ii ) Milk: 0.02 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 526.363 and 526.365 of this chapter.
38741.

#### RINZLER v. WESTINGHOUSE ELECTRIC CORPORATION.

Decided February 27, 1961.

*Carpenter, Karp & Mathews, Ferrin Y. Mathews,*for plaintiff in error.

*Jones, Bird & Howell, Trammell Vickery, Eugene T. Branch,*contra.

*202Jordan, Judge.

The question for determination by this court is whether or not there was sufficient evidence to support the verdict for the plaintiff. The evidence is uncontradicted that the plaintiff sold certain goods to the defendant on open account, that the defendant received said goods, and refused to pay for them, leaving a balance due on said account of $11,986.74. The defendant contends, however, that he was entitled to a credit against said account in the amount of $11,195.25 on the basis of the alleged agreement as set forth above.

The agreement between the plaintiff and the defendant as to' the advertising costs was an oral one and the evidence is conflicting as to its exact terms. Under the defendant’s version of the agreement, he was to receive the same deal as Georgia Power Co. and Davison-Paxon Co. with reference to advertising the plaintiff’s products. Under the plaintiff’s version, the agreement was simply to the effect that the plaintiff would pay 50 percent of the cost of the defendant’s television, radio and newspaper advertising, which was their regular cooperative advertising plan. The evidence is clear that all advertising had to be approved in advance by the plaintiff in order for the ads to qualify for the 50 percent credit, and that the defendant was not authorized to run any item of advertising under this plan without such prior approval. It is also undisputed that the plaintiff did participate in and pay at least 50 percent of the cost of all advertising done by the defendant with reference to the plaintiff’s products. There is, therefore, evidence to justify a finding that the plaintiff had fully performed its contract with the defendant relative to the advertising costs.

Even if the trial judge had adopted the defendant’s version of the contract, the defendant failed to prove the amount of credit, if any, to which he was entitled. The burden of establishing his affirmative defense was on the defendant and the evidence must show his right to recover as well as the specific amount to which he might be entitled. *Code*§ 81-801; *Smith v. Hilton & Dodge Lmbr. Co.,*13 Ga. App. 785 (80 S. E. 25).

The evidence is in agreement that Georgia Power Co. was paid on the same basis as the defendant and that Davison-*203Paxon Co. was paid 75 percent of its published vendor rate. However, the defendant offered no evidence that such payment amounted to more than 50 percent of the actual cost of such advertising.

The defendant having failed to show any specific credit to which he was entitled and the evidence being sufficient to support the verdict for the plaintiff in the full amount of the claim, the judgment of the court denying the defendant’s motion for a new trial on the general grounds only was not error.

*Judgment affirmed.*

*Townsend, P. J., Carlisle and Frankum, JJ., concur.*
# C_2014303EN.01000301.xml

| 8.9.2014 | EN | Official Journal of the European Union | C 303/3 |
| --- | --- | --- | --- |

8.9.2014

EN

Official Journal of the European Union

C 303/3

---

Request for a preliminary ruling from the Sąd Okręgowy w Częstochowie (Poland) lodged on 20 January 2014 — Ryszard Pańczyk v Dyrektor Zakładu Emerytalno-Rentowego Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie

(Case C-28/14)

2014/C 303/04

Language of the case: Polish

Referring court

Referring court

Sąd Okręgowy w Częstochowie

Parties to the main proceedings

Parties to the main proceedings

Applicant: Ryszard Pańczyk

Applicant:

Defendant: Dyrektor Zakładu Emerytalno-Rentowego Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie

Defendant:

By order of 12 June 2014, the Court of Justice held that it manifestly lacks jurisdiction to reply to the questions submitted by the Sąd Okręgowy w Częstochowie.

---
§ 522.2690 Zinc gluconate. ( a ) *Specifications.* Each milliliter of solution contains 13.1 milligrams zinc as zinc gluconate neutralized to pH 7.0 with L-arginine.
( b ) *Sponsor.* See No. 011788 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* The volume injected into each testicle is based on testicular width as determined by measuring each testicle at its widest point using a metric scale (millimeter) caliper.
( 2 ) *Indications for use.* Intratesticular injection for chemical sterilization of 3- to 10-month-old male dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[68 FR 26995, May 19, 2003, as amended at 76 FR 79064, Dec. 21, 2011; 87 FR 76422, Dec. 14, 2022]
§ 520.1920 Prochlorperazine and isopropamide. ( a ) *Specifications.* Each capsules contains either: ( 1 ) 3.33 milligrams of prochlorperazine (as the dimaleate) and 1.67 milligrams of isopropamide (as the iodide); or
( 2 ) 10 milligrams of prochlorperazine (as the dimaleate) and 5 milligrams of isopropamide (as the iodide).
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* ( i ) Capsules described in paragraph (a)(1) of this section are administered orally to dogs weighing from 4 to 15 pounds at the rate of 1 capsule twice daily. These capsules are administered orally to dogs weighing from 16 to 30 pounds at the rate of 1 or 2 capsules twice daily. For dogs weighing less than 4 pounds, administer orally an appropriate fraction of the contents of one of these capsules.
( ii ) Capsules described in paragraph (a)(2) of this section are given to dogs weighing 30 pounds and over at the rate of 1 capsule twice daily.
( 2 ) *Indications for use.* For the treatment of gastrointestinal disturbances associated with emotional stress.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28827, May 20, 2014]
§ 522.1362 Melarsomine powder for injection. ( a ) *Specifications.* The drug consists of a vial of lyophilized powder containing 50 milligrams of melarsomine dihydrochloride which is reconstituted with the provided 2 milliliters of sterile water for injection.
( b ) *Sponsor.* See Nos. 000010 and 086073 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer only by deep intramuscular injection in the lumbar muscles (L3-L5).
( 2 ) *Indications.* Treatment of stabilized, class 1, 2, and 3 heartworm disease (asymptomatic to mild, moderate, and severe, respectively) caused by immature (4 month-old, stage L5) to mature adult infections of *Dirofilaria immitis* in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[60 FR 49340, Sept. 25, 1995, as amended at 79 FR 16191, Mar. 25, 2014; 82 FR 21690, May 10, 2017; 84 FR 39184, Aug. 9, 2019]
§ 346.52 Labeling of permitted combinations of anorectal active ingredients. Indications, warnings, and directions for use, respectively, applicable to each ingredient in the product may be combined to eliminate duplicative words or phrases so that the resulting information is clear and understandable. ( a ) *Statement of identity.* For a combination drug product that has an established name, the labeling of the product states the established name of the combination drug product, followed by the statement of identity established in § 346.50(a). For a combination drug product that does not have an established name, the labeling of the product states the statement of identity established in § 346.50(a).
( b ) *Indications.* The labeling of the product states, under the heading “Indications,” the indication(s) for each ingredient in the combination, as established in the indications sections of this subpart.
( c ) *Warnings.* The labeling of the product states, under the heading “Warnings,” the warning(s) for each ingredient in the combination, as established in the warnings sections of this subpart.
( d ) *Directions.* The labeling of the product states, under the heading “Directions,” directions that conform to the directions established for each ingredient in the directions sections of this subpart. When the time intervals or age limitations for administration of the individual ingredients differ, the directions for the combination product may not exceed any maximum dosage limits established for the individual ingredients in the applicable OTC drug monograph.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM WESTERN
WIRELESS CONSOLIDATED BALANCE SHEET AND STATEMENT OF OPERATIONS AS OF AND FOR
THE NINE MONTHS ENDED SEPTEMBER 30, AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH 10-Q.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                           8,864
<SECURITIES>                                         0
<RECEIVABLES>                                   82,458
<ALLOWANCES>                                     9,795
<INVENTORY>                                      8,882
<CURRENT-ASSETS>                               107,530
<PP&E>                                         579,230
<DEPRECIATION>                                 260,289
<TOTAL-ASSETS>                               1,091,434
<CURRENT-LIABILITIES>                           83,351
<BONDS>                                      1,195,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       685,841
<OTHER-SE>                                   (874,096)
<TOTAL-LIABILITY-AND-EQUITY>                 1,091,434
<SALES>                                         16,680
<TOTAL-REVENUES>                               409,458
<CGS>                                           25,854
<TOTAL-COSTS>                                  377,969
<OTHER-EXPENSES>                              (80,275)
<LOSS-PROVISION>                                13,748
<INTEREST-EXPENSE>                              71,761
<INCOME-PRETAX>                              (147,990)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (47,338)
<DISCONTINUED>                               (100,652)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (147,990)
<EPS-BASIC>                                   (1.93)
<EPS-DILUTED>                                   (1.93)


</TABLE>